| 中文名称 | 顺式-3-(8-氨基-1-(2-苯基喹啉-7-基)咪唑并[1,5-a]吡嗪-3-基)-1-甲基环丁醇; 林西替尼 |
|---|---|
| 英文名称 | Linsitinib (Synonyms: OSI-906; Cis-3-(8-Amino-1-(2-phenylquinolin-7-yl)imidazo[1,5-a]pyrazin-3-yl)-1-methylcyclobutan-1-ol) |
| CAS号 | 867160-71-2 |
| 分子式 | C26H23N5O |
| 分子量 | 421.49 |
| 外观 | White to yellow powder |
| 储存条件 | Dry, dark and at 0 - 4 ℃ for short term (days to weeks) or -20 ℃ for long term (months to years). |
Linsitinib (formerly OSI-906; OSI 906) is a firs-in-class, ATP-competitive and orally bioavailable dual inhibitor of and insulin receptor (IR) and insulin-like growth factor-1 receptor (IGF-1R) with potential antitumor activity. It exhibits modest potency against InsR with an IC50 of 75 nM, and it has no activity against other kinases like Abl, ALK, BTK, EGFR, FGFR1/2, PKA, and so on. In cell-free assays, it inhibits IGF-1R with an IC50 of 35 nM.
Tags: buy Linsitinib | purchase Linsitinib | Linsitinib cost | order Linsitinib | Linsitinib chemical structure | Linsitinib in vivo | Linsitinib in vitro | Linsitinib formula | Linsitinib molecular weight
© 2020-2024 凯立德生物医药技术(上海)有限公司 版权所有
沪ICP备15046197号-3
沪公网安备31011502007856号
Designed by Kuanersoft